Rajeev M. Shah, Director at Cytek Biosciences, Inc. (CTKB), bought 883,730 shares at $12.89 ($11.4M) on 2022-03-02, disclosed to the SEC on 2022-03-02.
Open-market purchase of $11.4M CTKB by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.97 | 8,746 | $113K | 1.0% |
| 2 | $12.97 | 8,746 | $113K | 1.0% |
| 3 | $12.98 | 294,864 | $3.8M | 33.4% |
| 4 | $12.98 | 294,864 | $3.8M | 33.4% |
| 5 | $12.89 | 138,255 | $1.8M | 15.6% |
| 6 | $12.89 | 138,255 |
| $1.8M |
| 15.6% |
| Total | $12.95 avg | 883,730 | $11.4M | 100% |
| Filing → |
| SEPN | BUY | 2024-10-30 | $75.1M | — | Filing → |
| AVTE | BUY | 2024-06-20 | $3.1M | — | Filing → |
| HOWL | BUY | 2023-01-10 | $4.1M | — | Filing → |